Connor Kathryn A, Falvey Jennifer, Rappaport Stephen
Department of Pharmacy Practice and Administration, St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY 14618, USA.
Cardiovascular Pharmacy, University of Rochester Medical Center, Rochester, NY 14642, USA.
J Clin Med Res. 2022 Jul;14(7):282-286. doi: 10.14740/jocmr4744. Epub 2022 Jul 29.
A case of a negative outcome following systemic alteplase administration prior to extracorporeal membrane oxygenation (ECMO) in a kidney transplant patient with cardiac arrest is reported. A patient status-post kidney transplantation was admitted to the surgical intensive care unit (ICU) and experienced cardiac arrest after developing sudden-onset chest pain and shortness of breath. During cardiopulmonary resuscitation, alteplase 50 mg was administered intravenous push for suspected pulmonary embolism (PE) before the patient was evaluated for and started on veno-arterial ECMO. Within several hours, cardiopulmonary resuscitation needed to be reinitiated. Ultimately, the decision was made to cede further resuscitation efforts due to futility. A post-mortem examination included an immediate cause of death of acute myocardial infarction with extensive retroperitoneal hemorrhage. The role of ECMO is emerging in cardiac arrest, and should be considered as a management option before the administration of systemic thrombolysis in patients with increased bleeding risk.
报道了一例肾移植患者心脏骤停后在体外膜肺氧合(ECMO)前给予全身用阿替普酶后出现不良结局的病例。一名肾移植术后患者入住外科重症监护病房(ICU),在突发胸痛和呼吸急促后发生心脏骤停。在心肺复苏期间,在对患者进行评估并开始静脉-动脉ECMO治疗之前,因怀疑肺栓塞(PE)静脉推注了50mg阿替普酶。数小时内,需要重新开始心肺复苏。最终,由于复苏无效,决定放弃进一步的复苏努力。尸检显示直接死因是急性心肌梗死伴广泛腹膜后出血。ECMO在心脏骤停中的作用正在显现,对于出血风险增加的患者,在给予全身溶栓治疗之前,应将其视为一种治疗选择。